Rose is a managing editor at The American Journal of Managed Care® (AJMC®).
She has a BA in journalism & media studies and Spanish from Rutgers University. You can connect with Rose on LinkedIn.
Dr Fabian Lang on the Importance of Patient Involvement in CML Treatment Decisions
July 7th 2023In a disease such as chronic myeloid leukemia (CML), shared treatment decision-making between providers and patients is key, said Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany.
Read More
NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
July 7th 2023Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Read More
Race-Neutral Testing Could Reduce Bias in Lung Transplant Allocation, Study Suggests
June 29th 2023Interpreting spirometry with race-specific reference equations led to a lower Lung Allocation Score (LAS) for Black patients and higher LAS among White patients, which could potentially contribute to racially biased allocation of lung transplants.
Read More
Earlier Use of CAR T Cells Holds Promise in Blood Cancers, but Access Remains an Issue
June 23rd 2023A panel of experts at the American Society of Clinical Oncology Annual Meeting presented the latest research and equity considerations for chimeric antigen receptor (CAR) T-cell therapy in hematological cancers.
Read More
ASCO, ESMO Panel Highlights Progress and Disparities in Lung and Colorectal Cancer Screening
June 22nd 2023A session chaired by ASCO and ESMO leadership included experts on the latest lung and colorectal cancer screening technologies and persistent disparities in screening access and uptake.
Read More
FDA Approves Talazoparib Plus Enzalutamide for mCRPC With HRR Gene Mutations
June 21st 2023Talazoparib in combination with enzalutamide showed a 55% reduction in the risk of disease progression or death for patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene mutations in the phase 3 TALAPRO-2 trial.
Read More
Timely Initiation of Targeted Therapy for NSCLC Improves Outcomes, Study Finds
June 20th 2023Initiating targeted therapy for eligible patients with advanced non–small cell lung cancer (NSCLC) was found to improve outcomes, even when patients were started on nontargeted therapy but switched in a timely manner.
Read More
IMRT for Prostate Cancer Not Associated With Increased Risk of Second Primary Cancers, Study Finds
June 16th 2023There was no difference in second primary cancer risk among older adult male patients treated with intensity-modulated radiotherapy (IMRT) vs 3-dimensional conformal radiation therapy for prostate cancer.
Read More
Inequalities Within and Between Practices Contribute to NGS Testing Disparities in NSCLC
June 15th 2023A study presented at the American Society of Clinical Oncology Annual Meeting found practice- and provider-level racial and ethnic inequities in rates of next-generation sequencing (NGS) testing for patients with advanced non–small cell lung cancer (NSCLC) treated in the community setting.
Read More
Epcoritamab Approval Expands Treatment Armamentarium for DLBCL
June 9th 2023Tycel Phillips, MD, hematologist-oncologist at City of Hope in Duarte, CA, discussed the utility of epcoritamab in diffuse large B-cell lymphoma (DLBCL) and the potential impacts the bispecific antibody's recent approval will have in the community oncology setting.
Read More
Study Finds Patient Navigation Program Increases Lung Cancer Screening Rates in Urban Setting
June 9th 2023An abstract at the American Society of Clinical Oncology Annual Meeting showed disparities in lung cancer screening rates in an urban, multiethnic community, and patient navigation increased rates overall.
Read More
Axi-Cel Shows Favorable Safety, Efficacy in Real-World Study of Early FL Outcomes
June 9th 2023The autologous CAR T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated effectiveness and safety consistent with the ZUMA-5 trial when used in real-world settings to treat a broader population of patients with follicular lymphoma (FL).
Read More
Improving Access to Treatment Remains a Challenge in AML, Says Dr Jeffrey Lancet
June 9th 2023Much work is needed to address inequities and gaps in care access for patients with acute myeloid leukemia (AML), said Jeffrey Lancet, MD, chair of the Department of Malignant Hematology at Moffitt Cancer Center.
Read More
Disparities in Germline Genetic Testing Rates Exist, but Mechanisms Remain Unclear
June 9th 2023Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, discussed the importance of germline genetic testing in patients with triple-negative breast cancer and other cancer types.
Read More
Study Finds PSMA-PET May Hold Prognostic Utility in Prostate Cancer
June 9th 2023Research presented at the American Society of Clinical Oncology Annual Meeting found prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) to be associated with worse overall survival in prostate cancer without distant metastasis based on conventional imaging.
Read More
More Work Is Needed to Bring Clinical Trials to Underserved Patients, ASCO Panel Says
June 6th 2023While efforts are underway to improve access to cutting-edge oncology clinical trials for underserved patients, more work is needed to get the job done, said a panel of experts at the 2023 American Society of Clinical Oncology Annual Meeting.
Read More
ZUMA-7 Findings Show Earlier Is Better for Axi-Cel Use in R/R LBCL, Says Dr Jason Westin
June 5th 2023Jason Westin, MD, MS, FACP, director of the Lymphoma Clinical Research Program at the University of Texas MD Anderson Cancer Center, gave insight the ZUMA-7 trial of axicabtagene ciloleucel (axi-cel) in relapsed or refractory large B-cell lymphoma (R/R LBCL) and the study's implications in the broader LBCL landscape.
Read More
Social Determinants of Health Impact Germline Testing Rates Among Patients With TNBC
June 4th 2023Barb Kunz, MS, LCGC, senior genetic counselor at the US Oncology Network, shared insight on a study of social determinants of health in the context of germline genetic testing for triple-negative breast cancer (TNBC) in the community oncology setting.
Read More
Osimertinib Shows Significant OS Benefit in Patients With Resected, EGFRm NSCLC
June 4th 2023Roy S. Herbst, MD, PhD, deputy director of Yale Cancer Center and lead investigator for ADAURA, said the results erase any doubts about the use of osimertinib in early non–small cell lung cancer (NSCLC) for patients with EGFR mutations.
Read More
Dr Dennis Slamon on What Sets the NATALEE Trial Apart From Other Breast Cancer Studies
June 3rd 2023Dennis Slamon, MD, PhD, lead investigator on the NATALEE trial of ribociclib plus hormonal therapy in hormone receptor–positive, HER2-negative early-stage breast cancer, discussed the study's broad population and potential payer reactions.
Read More
ATS 2023 Abstracts Highlight Risk Factors for COPD Outside of Smoking
May 24th 2023A range of posters presented at the 2023 American Thoracic Society (ATS) International Conference highlighted a plethora of risk factors for pulmonary conditions in adulthood outside of tobacco smoking history.
Read More
Comorbidities Among Patients With COPD Impact Outcomes, Require Further Research
May 24th 2023A symposium at the 2023 American Thoracic Society International Conference highlighted common comorbidities that warrant consideration in patients who present with chronic obstructive pulmonary disease (COPD).
Read More